Zacks rates AmSurg stock a ‘hold’

Zacks has lowered its rating of AmSurg stock from “buy” to “hold,” according to The Legacy.

Advertisement

AmSurg stock has a 52-week low of $45.19 and a 52-week high of $72.85. AmSurg has a market cap of $3.36 billion, according to the report.

More articles on transactions and valuation issues:
Physicians file CON for new surgery center in Vermont: 4 things to know
5 things to know about Tenet’s cash flow
12 questions to ask potential “strategic” ASC corporate partners

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in ASC Transactions & Valuation Issues

Advertisement

Comments are closed.